Related Experiment Videos
Percutaneous mitral balloon valvuloplasty.
C E Mayes1, J E Cigarroa, R A Lange
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-9047, USA.
Clinical Cardiology
|September 24, 1999
Summary
Symptomatic mitral stenosis (MS) patients require intervention. Percutaneous mitral balloon valvuloplasty and surgical options offer comparable outcomes, with balloon valvuloplasty demonstrating over 90% success rates.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Rheumatic heart disease is the predominant cause of mitral stenosis (MS).
- Symptomatic patients with MS unresponsive to medical management require procedural intervention.
Purpose of the Study:
- To compare the efficacy and outcomes of percutaneous mitral balloon valvuloplasty (PMBV) versus surgical mitral valvular surgery for symptomatic MS.
- To outline the factors influencing the choice between PMBV and surgical intervention.
Main Methods:
- Review of current treatment guidelines and clinical outcomes for MS.
- Analysis of success rates, complication profiles, and long-term results for both PMBV and surgical commissurotomy/replacement.
Main Results:
- PMBV achieves a success rate exceeding 90%.
- Outcomes for experienced operators performing PMBV and open surgical commissurotomy are comparable in both acute and long-term phases.
- Complication rates for PMBV include mortality (0-1%), moderate-to-severe regurgitation (3-5%), and systemic embolization (1-3%).
Conclusions:
- PMBV is a highly successful treatment for symptomatic MS.
- The selection between PMBV and surgery depends on patient preference and detailed echocardiographic assessment of valve morphology.
- Both PMBV and surgical commissurotomy offer comparable results when performed by experienced teams.